Key facts
- BoobyBiome’s last known valuation is $17.2M (Sep 2025).
- It has raised $4.4M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Innovate UK, Venrex Investment Management, XFactor Ventures, Empirical Ventures, The Helm — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for BoobyBiome
- ·The full record, as it builds
Funding rounds
No funding rounds for BoobyBiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BoobyBiome
Operator of a microbiome research platform intended to improve infant health. The company develops probiotic supplements for babies that are born prematurely and is developing formula milk probiotics to make the closest possible substitute for breast milk, enabling babies to consume the beneficial bacteria found in breast milk that support their gut health and immune system.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 10
- Website
- boobybiome.com/
- Ownership
- Privately Held (backing)
BoobyBiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BoobyBiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BoobyBiome in its N-PORT filings yet. We sweep new filings monthly.